World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: EUCTR
Last refreshed on: 16 December 2019
Main ID:  EUCTR2019-001565-33-GB
Date of registration: 01/11/2019
Prospective Registration: No
Primary sponsor: Ra Pharmaceuticals, Inc.
Public title: Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis
Scientific title: A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects with Generalized Myasthenia Gravis - RAISE-XT
Date of first enrolment: 30/10/2019
Target sample size: 200
Recruitment status: Authorised-recruitment may be ongoing or finished
URL:  https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-001565-33
Study type:  Interventional clinical trial of medicinal product
Study design:  Controlled: no Randomised: no Open: no Single blind: no Double blind: no Parallel group: no Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: no Other: no Number of treatment arms in the trial: 1  
Phase:  Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): no Therapeutic confirmatory - (Phase III): yes Therapeutic use (Phase IV): no
Countries of recruitment
Canada France Germany Italy Japan Norway Spain United Kingdom
United States
Contacts
Name: Clinical Trial Information   
Address:  87 Cambridge Park Drive MA, 02140 Cambridge United States
Telephone: +1 617 4014060
Email: trials@rapharma.com
Affiliation:  Ra Pharmaceuticals, Inc
Name: Clinical Trial Information   
Address:  87 Cambridge Park Drive MA, 02140 Cambridge United States
Telephone: +1 617 4014060
Email: trials@rapharma.com
Affiliation:  Ra Pharmaceuticals, Inc
Key inclusion & exclusion criteria
Inclusion criteria:
To be eligible for this study, subjects must meet ALL of the following inclusion criteria:
1.Completion of a qualifying Ra Pharmaceuticals sponsored zilucoplan study
2.Able to provide informed consent, including signing and dating the informed consent form (ICF)
3.Vaccination with a quadrivalent meningococcal vaccine and, where available, meningococcal serotype B vaccine. A booster vaccination should also be administered as clinically indicated, according to the local SOC, for subjects who have been previously vaccinated against Neisseria meningitidis
4.Female subjects of childbearing potential must have a negative urine pregnancy test within 24 hours prior to the first dose of study drug
5.Sexually active female subjects of childbearing potential (i.e., women who are not postmenopausal or who have not had a hysterectomy, bilateral oophorectomy, or bilateral tubal ligation) and all male subjects (who have not been surgically sterilized by vasectomy) must agree to use effective contraception during the study. Postmenopausal women are, for the purposes of this protocol, defined as women who have gone 12 consecutive months without menstruation

Are the trial subjects under 18? no
Number of subjects for this age range: 0
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 150
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 50

Exclusion criteria:
Subjects who meet ANY of the following exclusion criteria must be excluded from the study:
1.Pregnant, planning to become pregnant, or nursing female subjects
2.With the exception of a prior zilucoplan trial, participation in another concurrent clinical trial involving an experimental therapeutic intervention (participation in observational studies and/or registry studies is permitted)
3.Unable or unwilling to comply with the requirements of the study
4.Did not start any disallowed medication per the exclusion criteria from the qualifying zilucoplan study or alter the dose of any other concomitant medication, unless medically indicated
5.Any new or worsening medical condition (since entry into the qualifying zilucoplan study) or any other reason that, in the opinion of the investigator or Sponsor, would disqualify the subject from participation in this study



Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes
Health Condition(s) or Problem(s) studied
Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Generalized Myasthenia Gravis
MedDRA version: 20.0 Level: LLT Classification code 10028415 Term: Myasthenia System Organ Class: 100000004859
Intervention(s)

Product Name: Zilucoplan
Pharmaceutical Form: Solution for injection in pre-filled syringe
INN or Proposed INN: Zilucoplan
CAS Number: 1841136-73-9
Current Sponsor code: RA101495
Concentration unit: mg/ml milligram(s)/millilitre
Concentration type: equal
Concentration number: 40-

Primary Outcome(s)
Secondary Objective: Not applicable
Primary end point(s): Efficacy endpoints:
•MG-ADL Score
•QMG Score
•MG-QOL15r
•MGC Score
Safety endpoints
Main Objective: •To provide access to zilucoplan for subjects with gMG who have completed a qualifying Ra Pharmaceuticals sponsored zilucoplan study and who wish to continue receiving zilucoplan
•To evaluate the long-term efficacy of zilucoplan in subjects with gMG who have completed a qualifying Ra Pharmaceuticals sponsored zilucoplan clinical study
•To evaluate the long-term safety and tolerability of zilucoplan in subjects with gMG who have completed a qualifying Ra Pharmaceuticals sponsored zilucoplan clinical study
Timepoint(s) of evaluation of this end point: during each visit
Secondary Outcome(s)
Secondary end point(s): Not applicable
Timepoint(s) of evaluation of this end point: Not applicable
Secondary ID(s)
RA101495-02.302
Source(s) of Monetary Support
Ra Pharmaceuticals, Inc.
Secondary Sponsor(s)
Ethics review
Status: Approved
Approval date:
Contact:
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey